MA
Mangalam Drugs and Organics Ltd (MANGALAM)
₹31.39
Mkt cap
₹54 Cr
P/E ratio
—
P/B
0.48
Div yield
0.00%
ROE
−34.80%
ROCE
−14.00%
EPS (TTM)
—
Book value
₹65
52W range
23–77
Sector
Healthcare
Price history
Previous close
Incorporated in 1977, Mangalam Drugs & Organics Ltd manufactures Active Pharmaceutical Ingredients and Intermediates. [1]
NSE MANGALAMBSE 532637
Health check
Cautious
ProfitabilityWeak
GrowthLow
TechnicalsNeutral
52-week range
−59.12% from high₹31
₹23+37.68% from low₹77
Current
₹31.39
Prev close
₹30.90
Day
+1.59%
Price performance
1D
+2.49%
1W
−1.77%
1M
−0.85%
3M
+11.36%
6M
+5.85%
1Y
−57.80%
YTD
+3.53%
Financials
Revenue, profit & margin
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 87.46 | 81.56 | 97.34 | 102.24 | 76.53 | 79.94 | 88.71 | 72.78 | 57.21 | 49.54 | 58.38 | 67.29 | 57.12 | |
| Expenses | 90.94 | 79.37 | 90.36 | 90.54 | 68.34 | 71.25 | 79.94 | 62.88 | 61.86 | 52.37 | 59.96 | 72.65 | 56.22 | |
| Operating Profit | -3.48 | 2.19 | 6.98 | 11.70 | 8.19 | 8.69 | 8.77 | 9.90 | -4.65 | -2.83 | -1.58 | -5.36 | 0.90 | |
| OPM % | -3.98% | 2.69% | 7.17% | 11.44% | 10.70% | 10.87% | 9.89% | 13.60% | -8.13% | -5.71% | -2.71% | -7.97% | 1.58% | |
| Other Income | 0.02 | 0.03 | 0.00 | 0.05 | 0.02 | 0.14 | 0.13 | 0.47 | 0.14 | 0.03 | 0.22 | 0.09 | 0.11 | |
| Interest | 3.41 | 3.24 | 3.31 | 3.95 | 3.75 | 3.67 | 3.49 | 4.03 | 4.04 | 5.03 | 4.05 | 3.08 | 3.68 | |
| Depreciation | 3.42 | 3.73 | 3.62 | 3.86 | 3.87 | 3.97 | 3.93 | 4.61 | 4.38 | 4.53 | 4.37 | 4.56 | 3.99 | |
| Profit before tax | -10.29 | -4.75 | 0.05 | 3.94 | 0.59 | 1.19 | 1.48 | 1.73 | -12.93 | -12.36 | -9.78 | -12.91 | -6.66 | |
| Tax % | -7.29% | -25.05% | -920.00% | 9.90% | -355.93% | -125.21% | 5.41% | 90.75% | 6.19% | -41.42% | 0.00% | 1.16% | 13.36% | |
| Net Profit | -9.54 | -3.56 | 0.50 | 3.55 | 2.68 | 2.69 | 1.40 | 0.15 | -13.73 | -7.25 | -9.78 | -13.06 | -7.55 | |
| EPS in Rs | -6.03 | -2.25 | 0.32 | 2.24 | 1.69 | 1.70 | 0.88 | 0.09 | -8.67 | -4.58 | -6.18 | -8.25 | -4.77 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +1.91% · closed higher next day 1 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 12 Aug '26◦ |
| Earnings day | +1.91% |
| +1 day | +2.93% |
| +5 days | −1.17% |
| +15 days | +11.11% |
| +30 days | +16.72% |
| Filing |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202635.65%Promoter
Promoters35.65%
FIIs0.11%0.21
Public64.24%0.21
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Mangalam Drugs | ₹34.26 | — | 54 | 0.00% | −8 | +45.01% | 57 | −0.16% | −14.01% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports15
Concall transcripts3
Credit ratings6
Announcements5
Defaults under Para A sub-paragraph 6 of Schedule III-Subsequent Disclosure 15 Sep - Company disclosed 30+ day default on loans to Bank of Maharashtra and Bank of Baroda, overdue Rs 1,557.27 lakh.Announcement under Regulation 30 (LODR)-Change in Management 15 Sep - Board appointed Prabhakar Raghunath Zavar as independent director for five years, subject to shareholder approval.Board Meeting Outcome for Outcome Of Board Meeting Pursuant To Regulation 30 Of LODR For Appointment Of Mr. Prabhakar Zavar As Additional Indepedent Director ( Non-Executive) For Term Of 5 Years Wef. 15/09/2026, Subject To Consent Of Shareholders At Ensuing EGM. 15 Sep - Board appointed Mr. Prabhakar Raghunath Zavar as additional independent director for five years.Announcement under Regulation 30 (LODR)-Newspaper Publication 1 Sep - Newspaper publication regarding Notice of 53rd Annual General Meeting to be held on 23rd September, 2026 and information on E-voting.Reg. 34 (1) Annual Report. 31 Aug - 53rd AGM on September 23, 2026; annual report issued, auditor appointments and related-party approvals proposed.